|Day Low/High||130.33 / 178.50|
|52 Wk Low/High||17.68 / 153.87|
A now-overbought market leaves few values available among equities.
When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.
WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.
So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.
The negatives are being shaken off like a first time rider on a long-time bull which means long remains the name of the game.
I've been long Merck for a long time, since way before this pandemic became part of our lives.
The return of NYSE floor traders is symbolic of the return to normalcy, as vaccine candidate manufacturers are scaling up for mass production.
The market may be down but, once again, the decline's about the White House getting re-tough on China.
As State economies begin the slow process of reopening, the Fed is there to support market function. Facebook's latest e-commerce foray has investors cheering.
Bull and bear markets are occurring simultaneously and that makes for good stock-picking but great difficulty if you are trying to trade the major indices.
Expect more fiscal and monetary support and don't expect a full return to previous economic activity for quite some time.
Headlines questioning phase-one trial data by Moderna spurred late selling as this market is still a bear.
So, let me get this straight. Moderna rushes to do a secondary last night even though they don't need the money yet. To me, if the vaccine works and they need to produce it in quantity, the stock will be many multiples higher than today -- and there...
Remarkable story about the vaccine czar and Moderna .
* I don't yearn or expect another yesterday, today. * Let it be... "Yesterday All my troubles seemed so far away Now it looks as though they're here to stay Oh, I believe in yesterday Suddenly I'm not half the man I used to be There's a shadow hangi...
Watching Moderna, Microsoft and FedEx as risk continues to be a central market theme, despite Monday's rally.
Let's step back and look at this market that has abandoned all sorts of safety and went all in on the stocks of companies based on the Fed's words and a promising Moderna study.
I'm long this name, as I am several of the others involved. Will I add on a day like this?
* The bears' skepticism (and cautious market positioning) coupled with their collective cynicism towards medical and scientific innovation, and the inevitability of the curve's flattening along with an "all in" Fed, have fueled the market recovery f...
Jerome Powell hit the airwaves with some words of caution and comfort. Nvidia is running into earnings.
GE's problem can be summarized in one sentence: The company is burning cash.
Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.
There are simply an immense number of health and technology and safety companies coupled with businesses that thrive when you have to stay home.
Thursday's rally was sparked by news that Moderna's Covid-19 vaccine candidate is moving to Phase II testing.
I get this rally -- it's based on more than a breaking branch this time, but there are still many uncertainties.
I'm staying long this name, and I'm staying long PFE and JNJ, and I'm staying long GILD and ABT. You know why? Because I'm optimistic.
As Treasury heads for longer-dated issuance and names like PTON run higher on earnings, selloffs late in the trading day continue.
PFE is collaborating with German drugmaker BioNTech in the effort to find a well tolerated, effective vaccine.
The market sold off on Thursday after close as big hitters, including Amazon, reported earnings.